Gilead Viread Use Beyond HIV Drug-Experienced Patients Questioned By Cmte
Executive Summary
Gilead's HIV drug Viread could be limited to use in treatment-experienced patients, a majority of FDA's Antiviral Drugs Advisory Committee suggested Oct. 3.
You may also be interested in...
Gilead Viread Virology Data Will Distinguish HIV Drug In Physician Promotions
Gilead will highlight Viread virology data to distinguish the HIV treatment in physician promotions
Gilead Viread Virology Data Will Distinguish HIV Drug In Physician Promotions
Gilead will highlight Viread virology data to distinguish the HIV treatment in physician promotions
Gilead Viread approval
FDA approves tenofovir Oct. 26 for treatment of HIV-1 infection when used in combination with other antiretroviral agents. Gilead expects Viread will be in pharmacies "within days." FDA's Antiviral Drugs Advisory Committee suggested Oct. 3 that use of Viread be limited to use in treatment-experienced patients (1"The Pink Sheet" Oct. 8, p. 30)